Aptahem

E-Projection (read more about e-Projection) has performed a due diligence on Apta-1 including a number of follow-up meetings with Aptahem. They see the potential in the project, which made them decide to enter into a business development collaboration with Aptahem based on success fee terms.

Aptahem sees great advantages in cooperating with the Japanese company, which with its experience and knowledge of the domestic pharmaceutical market sees a faster and more efficient way to reach Apta-1's potential message. Japan represents one of the world's three largest pharmaceutical markets.

CEO Mikael Lindstam comments:

"I am very happy to announce that we are now entering into a collaboration with e-Projection to accelerate our partnering opportunities with Japanese pharmaceutical players. With all their connections in the Japanese pharma industry, partly through individual experiences and partly through e-Projection's work, we feel great confidence in their ability to guide us towards potential partnering opportunities. E-Projection's screening work on Apta-1 has been important to us, which is confirmed by the collaboration agreement entered into and the potential they see in the drug candidate."

For further information:

Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
E-mail: ml@aptahem.com

About Aptahem

Aptahem AB (APTA) is a clinical stage biotechnology company that develops RNA-based pharmaceuticals for the treatment of acute, life-threatening conditions in which a combination of coagulation, inflammation and tissue damage are involved. The company's lead candidate, Apta-1, is currently in early clinical phase. Apta-1 has in preclinical studies, by its anti-thrombotic, immunomodulating and tissue repairing characteristics, shown very positive and promising results as treatment for sepsis and critical conditions associated with sepsis. For more information, please visit www.aptahem.com.